BACKGROUND: After a pilot study on @entity1489 screening was performed between 2003 and 2004 in Schleswig-Holstein, Germany, the country implemented what to the authors' knowledge is the first nationwide @entity1489 screening program in the world in 2008. The objective of the current study was to provide details regarding mortality trends in Schleswig-Holstein and Germany in relation to the screening. METHODS: Annual age-standardized mortality rates for @entity320 (using the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems [ICD-10] code C43) and @entity5 of ill-defined, secondary, and unspecified sites (ICD-10 code C76-C80) were analyzed. The European Standard population was used for age standardization. A bias analysis was performed to estimate the number of @entity204 that may have been incorrectly counted as ICD-10 code C76-C80 when the @entity320 mortality declined in Schleswig-Holstein. RESULTS: The observed mortality decline in Schleswig-Holstein 5 years after the pilot study was accompanied by a considerable increase in the number of @entity204 due to @entity5 of ill-defined, secondary, and unspecified sites (ICD-10 code C76-C80) that is not explainable by an increase in the incidence of these @entity5 . Incorrect assignment of 8 to 35 and 12 to 23 @entity204 per year among @entity1 and @entity1 , respectively, as ICD-10 code C76-C80 during 2007 through 2010 could explain the transient @entity320 mortality decline observed in Schleswig-Holstein. Five years after implementation of the program, the nationwide @entity320 mortality increased (age-standardized rate change of +0.4 per 100,000 @entity1 -years [95% confidence interval, 0.2-0.6] in @entity1 and +0.1 per 100,000 @entity1 -years [95% confidence interval, -0.1 to 0.2] in @entity1 ). CONCLUSIONS: Although the current analyses raise doubts that the @entity1489 screening program in Germany can reduce the @entity1489 mortality rate, the authors do not believe the program should be immediately stopped. Further in-depth evaluations are required. @entity5 2016;122:432-437.    2015 American @entity5 Society.

Does XXXX screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'person'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant neoplasms', 'Cancer', 'neoplasms'] @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['skin melanoma deaths', 'deaths'] @entity320 :: ('MESH:D008545', 'Disease') :: ['skin melanoma']
@entity1489 :: (MESH:D012878,Disease) :: ['skin cancer']
